|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.585 USD | +0.42% |
|
-6.64% | -83.68% |
Tenax Therapeutics, Inc. has announced the resignation of John Kelley as CEO and its board of directors. Effective April 3, 2017, John Kelley has agreed to provide consulting services to the company for a period of time following his resignation. The Company's Board of Directors appointed Michael Jebsen, the Company's current President and CFO, as Interim CEO, effective immediately upon Kelley's resignation.
Jebsen previously served as Interim CEO for the company from 2011 to 2013.
| 1st Jan change | Capi. | |
|---|---|---|
| -83.68% | 7.02M | |
| +17.96% | 44.96B | |
| +48.77% | 41.85B | |
| +1.17% | 42.65B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
TENAX THERAPEUTICS, INC. 
